Form 6-K GSK plc For: Jul 09

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/16/2026

1. SPY
2. ASML
3. PYPL
4. NVDA
5. JPM
6. AMZN
7. GOOGL
8. MSFT
9. SPCX
10. PNR

July 9, 2026 7:28 AM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Issued: 9 July 2026, London UK
 
Roy Jakobs to join GSK Board as Non-Executive Director

 
GSK plc (LSE/NYSE: GSK) has today announced that Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026. 
 
Mr Jakobs is currently Chief Executive Officer of Royal Philips, a global leader in health technology with sales of 17.8 billion EUR in 2025 and 65,000 employees worldwide, headquartered in Amsterdam, Netherlands.
 
Mr Jakobs has served as CEO of Royal Philips since 2022, and prior to that held international roles of increasing seniority after joining the company in 2010. Mr Jakobs has also held senior roles at other global companies including Shell and Elsevier, and holds a Master's in Business Administration (MBA).
  
Sir Jonathan Symonds, Chair of GSK said, "We are delighted to welcome Roy to the Board. His experience as CEO of a global health technology company, specialising in innovative adjacent technologies to biopharmaceuticals including patient monitoring, imaging, and intervention, will bring valuable perspective to Luke and the Board. Roy's values and approach to culture and purpose are highly aligned with our own, and he is well-placed to support GSK as we focus on accelerating growth and delivering better medicines for the patients who need them and greater value for shareholders."
 
Notes:

1.   The appointment of Mr Jakobs was made by the Board on the recommendation of the Nominations & Corporate Governance Committee. The Board agreed a target skills matrix for the role and was assisted and supported in candidate selection and evaluation by an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms. The Board satisfied itself that Mr Jakobs had the experience and time available to carry out the role.
 
2.   The Board has determined that Mr Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
 
3.   Mr Jakobs will receive the standard annual fee for a Non-Executive Director of £122,258. He will be required to build towards a share ownership requirement of GSK shares in accordance with the Company's shareholder approved Non-Executive Director Remuneration policy - currently two times the standard annual fee. 
 
4.   Mr Jakobs does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company's registered office.
 
5.   There are no further disclosures to be made in respect of Mr Jakobs' appointment under Listing Rule 6.4.8R.
 
6.   As of 13 July 2026, the Board of GSK will comprise:
 
Sir Jonathan Symonds CBE
 
Non-Executive Chair
 
Luke Miels
 
Chief Executive Officer
 
Julie Brown
 
Chief Financial Officer
 
Charles Bancroft
 
Senior Independent Non-Executive Director
 
Elizabeth McKee Anderson
 
Independent Non-Executive Director
 
Dr Hal Barron
 
Non-Executive Director
 
Dr Anne Beal
 
Independent Non-Executive Director
 
Wendy Becker CBE
 
Independent Non-Executive Director
 
Dr Hal Dietz
 
Independent Non-Executive Director
 
Roy Jakobs
 
Independent Non-Executive Director
 
Dr Jeannie Lee
 
Independent Non-Executive Director
 
Dr Gavin Screaton
 
Independent Non-Executive Director
 
Dr Vishal Sikka
 
Independent Non-Executive Director
 
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 09, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings